Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report
This case report (n=1) describes a woman with generalized anxiety disorder who experienced extreme anxiety, panic, and hopelessness during and up to three days after taking ayahuasca. This is the first description of a prolonged 'bad' trip in the literature.
Authors
- Jamie Hallak
- Rafael dos Santos
- Jaime Crippa
Published
Abstract
Background and aims Ayahuasca is a dimethyltryptamine- and β-carboline-rich hallucinogenic beverage traditionally used by indigenous groups of Northwest Amazonian for ritual and therapeutic purposes. Animal and human studies suggest that ayahuasca has antidepressant and anxiolytic potentials and has a good safety profile. However, anxiety-like reactions may also occur after ayahuasca intake, although they are rare.
Methods
Case report.
Results
Here, we describe a case of a non-medicated, symptom-free young female with generalized anxiety disorder, who experienced intense anxiety, panic, and hopelessness during and for 3 days after participating in an ayahuasca ritual. The symptoms appeared in the first hours after ayahuasca intake and were gradually reducing in the following hours/days, but were intense enough to cause significant suffering to her, who needed to seek psychiatric help and restarted pharmacological treatment.
Conclusions
Although “bad/horror trips” with anxiety features may occur during the acute effects of ayahuasca and other hallucinogens, to the best of our knowledge, this is the first report of a subacute/prolonged anxiety-like reaction to this substance. Ayahuasca should be used with caution in people with a history of anxiety disorders.
Research Summary of 'Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report'
Introduction
Ayahuasca is a traditional botanical hallucinogenic brew composed of Banisteriopsis caapi and Psychotria viridis, containing DMT and β-carbolines that together permit oral DMT to become systemically active. Earlier human and animal studies suggest anxiolytic and antidepressant effects of ayahuasca, and controlled administrations in healthy volunteers are generally well tolerated; the acute psychoactive window typically begins within 30–40 minutes, peaks around 1.5–2 hours, and resolves by 4–6 hours. While transient dysphoric reactions such as anxiety or paranoia can occur during the acute effects, prolonged or subacute anxiety-related adverse events have not been commonly reported in controlled settings, and long-term ritual users generally do not show increased psychopathology in observational studies, although selection biases may limit those findings. Santos and colleagues report a single-case description to document what they consider an uncommon prolonged anxiety-like reaction following ritual ayahuasca ingestion in a young woman with a prior diagnosis of generalized anxiety disorder (GAD). The report aims to characterise the clinical course, contextual factors, and possible mechanisms of the event, and to highlight implications for the use of ayahuasca in people with anxiety histories. This case is presented as, to the authors’ knowledge, the first scientific description of a subacute/prolonged anxiety reaction temporally associated with ayahuasca intake.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & C. Hallak, J. E. (2017). Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report. Journal of Psychedelic Studies, 1(1), 35-39. https://doi.org/10.1556/2054.01.2017.004
References (15)
Papers cited by this study that are also in Blossom
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Show all 15 referencesShow fewer
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Szmulewicz, A. G., Valerio, M. P., Smith, J. M. · International Journal of Bipolar Disorders (2015)
Cited By (2)
Papers in Blossom that reference this study
Gómez-Sousa, M., Jiménez-Garrido, D. F., Ona, G. et al. · Journal of Clinical Psychopharmacology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.